Key result
Colchicine and IL-1 antagonists effectively treat recurrent, incessant, and chronic pericarditis.
Why the study?
Eight years have passed since the European Guidelines for pericarditis management, and COVID-19 along with diverse non-infectious causes have shifted pericarditis epidemiology and necessitated differentiated therapeutic strategies.
Do colchicine and interleukin-1 antagonists improve outcomes in patients with incessant, recurrent, or chronic pericarditis?
Systematic Review
Do colchicine and interleukin-1 antagonists improve outcomes in patients with incessant, recurrent, or chronic pericarditis?
Highlights the growing role of colchicine and targeted biologic therapies like IL-1 antagonists in managing difficult-to-treat recurrent pericarditis.
Supports colchicine and IL-1 antagonists for recurrent pericarditis; confirms efficacy across viral and idiopathic cases in updated evidence synthesis.
Eight years have passed since the update of the European Guidelines for the management of pericarditis, almost 3 years of which the pandemic of the new coronavirus has been continuing. COVID-19 has changed the structure and the course of all cardiac diseases. At present there is no doubt that the dominant cause of pericarditis is the new coronavirus SARS-CоV-2. However, such non-infectious causes as systemic inflammatory diseases, paraneoplastic and postpericardiotomy syndromes that require a differentiated therapeutic strategy, remain relevant. This part of the systematic review addresses the treatment of incessant, recurrent, and chronic viral/idiopathic pericarditis. Particular attention is paid to publications on the effectiveness of the therapy with colchicine and interleukin-1 antagonists. The review of the medical resources such as PubMed, Google Scholar, UpToDate (publications from 01.1990 to 10.2022) was conducted, the issues of differentiated pericarditis therapy with various anti-inflammatory drugs were studied thoroughly.
No takes yet. Share an insight, caveat, or question.
Sukmarova et al. (2023) conducted a systematic review in Incessant, recurrent, and chronic viral/idiopathic pericarditis. Colchicine and interleukin-1 antagonists was evaluated. Colchicine and interleukin-1 antagonists are effective therapies for managing incessant, recurrent, and chronic viral or idiopathic pericarditis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: